Q2009 HCPCS Level II code: Injection, fosphenytoin, 50 mg phenytoin equivalent
Q2009 is the HCPCS code for “Injection, fosphenytoin, 50 mg phenytoin equivalent” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q2009Injection, fosphenytoin, 50 mg phenytoin equivalent
Short description: Fosphenytoin inj pe
HCPCS · United States
Medicare details
The indicators CMS publishes with Q2009 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Coverage statute
- 1861S2B
- Added
- Jul 1, 2000
Where Q2009 sits
- 1Q codesTemporary codes
- 2Active code Q2009Injection, fosphenytoin, 50 mg phenytoin equivalent
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q2009 mean?
Q2009 is the HCPCS code for “Injection, fosphenytoin, 50 mg phenytoin equivalent” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q2009?
CMS lists Q2009’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q2009
All Q codesQ0519Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-daysQ0520Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-daysQ0521Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescriptionQ1004New technology intraocular lens category 4 as defined in federal register noticeQ1005New technology intraocular lens category 5 as defined in federal register noticeQ2004Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 mlQ2017Injection, teniposide, 50 mgQ2026Injection, radiesse, 0.1 mlQ2028Injection, sculptra, 0.5 mgQ2034Influenza virus vaccine, split virus, for intramuscular use (agriflu)Q2035Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)Q2036Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)